Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.


GREY:ADXS - Post by User

Ayala Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by MissionIRon Feb 03, 2014 6:53pm
147 Views
Post# 22167754

Advaxis, Inc. (ADXS) Presenting at the 16th Annual BIO CEO &

Advaxis, Inc. (ADXS) Presenting at the 16th Annual BIO CEO &

Advaxis, Inc. (ADXS) Presenting at the 16th Annual BIO CEO & Investor Conference

Today before the opening bell, Advaxis announced that it will be presenting at the 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City in mid-February. Mr. Daniel J. O’Connor, Chief Executive Officer of Advaxis, will be presenting a company update at the conference on Tuesday, February 11, 2014 at 3:30 pm EST.

Those who wish to see the presentation are advised to visit the following link for a live webcast: https://www.veracast.com/webcasts/bio/ceoinvestor2014/08238316629.cfm.

Advaxis is a clinical-stage biotechnology company developing the next generation of cancer immunotherapies. Advaxis’ immunotherapies are based on a novel platform technology using live, attenuated bacteria to stimulate the immune system to selectively target cancer cells while reducing tumor defenses.

For more information, visit: www.advaxis.com

Please read full disclaimers at https://disclaimer.missionir.com


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities